BioToxtech Confident of Returning to Profit This Year: "The Two-Year Tunnel Is Over"

BioToxtech, a non-clinical CRO (Contract Research Organization) specialist listed on KOSDAQ, has announced that, after a prolonged industry downturn, it is poised for a full-fledged earnings turnaround this year.

The company plans not only to recover but also to accelerate the restoration of market confidence through record-high order performance and a strengthened shareholder-return strategy.

On the 23rd, BioToxtech declared this year to be the first year of its earnings turnaround in a "Letter to Shareholders." The company explained that although it went through a difficult period over the past two years due to reduced research and development (R&D) investment by both the private sector and the government, it has completed its structural overhaul by securing quality competitiveness and improving efficiency.

The results are already visible in the numbers. According to BioToxtech, in the fourth quarter of last year it recorded the second-highest quarterly order volume since its establishment, and its order backlog for 2025 stands at 41.5 billion won.

Given that it takes several quarters for non-clinical testing orders to be recognized as actual revenue, the order volume secured last year is expected to be fully reflected in steep sales growth starting this year.

This growth is underpinned by solid external credibility. In particular, the fact that Celltrion, a leading Korean bio company, participates as a major shareholder with an approximately 10.22% stake is regarded as an indicator of BioToxtech's technological capabilities and business stability. The two companies maintain a strategic partnership that goes beyond a simple equity relationship, and analysts say this will serve as a competitive edge in capturing non-clinical demand arising from the expansion of the biopharmaceutical market going forward.

Growth at KeyPrime Research, a non-human primate (NHP) specialist that is both a subsidiary and considered a future growth pillar, is also noteworthy. KeyPrime Research has been achieving record growth of more than 100% every year in both orders and sales.

Notably, about 50% of its revenue is generated from global clients in markets such as the United States and Europe. Building on this performance, KeyPrime Research recently initiated full-scale IPO (listing) procedures, including filing for the designation of an external auditor.

Together with the recovery in earnings, the company is also stepping up efforts to enhance shareholder value. BioToxtech plans to actively implement shareholder-return policies, including share repurchases and cancellations, while expanding non-deal roadshows (NDRs) and investor relations (IR) activities to increase communication with the market.

Previously, BioToxtech had disclosed a 1 billion won share repurchase program running from August last year through February 26 this year.

A BioToxtech official said, "After enduring the trials of the past two years, we are now preparing for a second leap forward," adding, "We will repay our shareholders' trust through earnings growth and transparent information disclosure."